Drug intelligence / Profile preview

Picomium

Development stage: Unknown
Lead developer: Malik Hassan Mehmood
Modality: Small Molecules
Administration: Oral

Overview

Picomium is a branded formulation of chromium picolinate (500 mcg) being investigated as an adjunctive therapy for adults with type 2 diabetes mellitus and diabetic renal impairment (diabetic nephropathy or chronic kidney disease). Developed by Dr. Malik Hassan Mehmood, it is a coordination complex of trivalent chromium (Cr³⁺) and picolinic acid. The drug acts by potentiating insulin signaling at the insulin receptor level, thereby improving glycemic control and potentially metabolic parameters in patients with renal complications. It has been evaluated in a phase 2 clinical trial as an add-on to stable antidiabetic medications.

Brand names: Picomium
Other names: chromium picolinate

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on Picomium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Picomium.

Explore the full profile